MMJ: Expands into Europe

Company News

by Jessica Amir

MMJ PhytoTech Ltd (ASX:MMJ) has signed a binding letter of intent (LOI) with a leading pharmaceutical distributor and retailer to expand into Europe.

The medicinal cannabis producer signed the binding letter of intent with for its Satipharm products to be marked and distributed throughout Scandinavia.

At the same time, the company announced its flagship cannabidiol product, Gelpell-CBD Microgel Capsules, can also now be purchased over the counter throughout pharmacies in Germany.

MMJ PhytoTech Ltd says this is not only a key milestone for the company, but serves as a significant value catalyst for shareholders. 

MMJ PhytoTech Ltd (ASX:MMJ) reported a consolidated loss of $4.5 million for the half-year to 31 December 2016.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.